Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index

Annals of Oncology

Volumn 15, Issue 9, 2004, Pages 1419-1424

  Bertz, H ^a   Zeiser, R ^a   Lange, W ^a   Fetscher, S ^a   Waller, C F ^a   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Age adjusted international prognostic index (aaIPI); Autologous stem cell transplantation (ASCT); Chemosensitive disease; High dose chemotherapy (HDCT); High grade B cell non Hodgkin's lymphoma (hg B NHL); Long term follow up

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; STEM CELL MOBILIZATION; SURVIVAL TIME;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, HIGH-GRADE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RECURRENCE; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 4644357447     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh353     Document Type: Article

References (37)

1. Devesa SS, Blot WJ, Stone BJ et al. Recent cancer trends in the United States. J Natl Cancer Inst 1995; 87: 175-182.
2. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023.
3. Martelli M, Gherlinzoni F, De Renzo A et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255-1262.
4. Perry AR, Goldstone AP. High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol 1998; 9 (Suppl 1): 9.
5. Kim D, Mauch P, Shaffer K et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993; 11: 1336-1341.
6. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1009.
7. Blayney DW, LeBlanc ML, Grogan T et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003; 21: 2466-2473.
8. Coiffier B, Lepage E. Prognosis of aggressive lymphoma: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989; 74: 558-562.
9. The International Non Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-992.
10. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has 'high-risk' disease? Blood 1994; 83: 1165-1171.
11. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.
12. Nademanee AP, Schmidt GM, O'Donnell MR et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992; 80: 1130-1133.
13. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and bone marrow registry. J Clin Oncol 2001; 19: 406-413.
14. Gianni AM, Bregni M, Siena S. 5-Year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs. MACOP-B therapy for diffuse large-cell lymphomas. Proc Am Soc Clin Oncol 1994; 13: 373-375.
15. Pettengell R, Radford JA, Morgenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586-589.
16. Verdonck LF, Van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggessive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-1048.
17. Martelli M, Vignetti M, Zinzani PL et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethason, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534-539.
18. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994; 12: 2543-2548.
19. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH 87-2. J Clin Oncol 1997; 15: 1131-1136.
20. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Int Med 1985; 102: 596-602.
21. O'Reilly SE, Hoskins P, Klimo P. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 1 (Suppl): 17.
22. Lennert K, Mohri N, Stein H. The histopathology of malignant lymphoma. Br J Haematol 1975; 31 (Suppl 1): 193.
23. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases in the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
24. Brugger W, Gramatzki M, Mertelsmann R et al. Early high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation (PBPC-T) in patients with high-risk aggressive non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1995; 14: 326a (Abstr).
25. Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in ist consideration. Cancer Chemother Rep 1966; 50: 163-170.
28. Blay JY, Gomez F, Sebban C et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998; 92: 3562-3568.
29. Shipp MA, Abeloff MD, Amman KH et al. International consensus conference on high-dose therapy with hematopoetic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-428.
30. Baro J, Richard C, Calavia J et al. Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features. Bone Marrow Transplant 1991; 8: 283-287.
31. Bertz H, Zeiser R, Lange W et al. No significant survival difference between high and low risk, high grade NHL (hgNHL) patients having undergone high dose chemotherapy (HDCT) with autologous stem cell transplantation (aSCT) during long-term follow-up. Blood 2003; 102: 734a (Abstr).
32. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high dose chemotherapy with granulocyte colony-stimulating factor and autologous stem cell transplantation support as first line therapy in high risk large cell lymphoma. J Clin Oncol 1997; 15: 491-496.
33. Sehn LH, Antin JH, Shulman LN et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoetic cell transplantation. Blood 1998; 91: 717-721.
34. Nadamanee A, Molina A, O'Donnell MR et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international prognostic index for high- and high-intermediate risk group. Blood 1997; 90: 3844-3849.
35. Santini G, Salvagno L, Leoni P et al. VACOP-B vs VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study group. J Clin Oncol 1998; 16: 2796-2801.
36. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 18: 1290-1293.
37. Milpied N, Deconinck E, Gaillard F et al. Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.